WATERTOWN, Mass.--(BUSINESS WIRE)--Exo Therapeutics, Inc., a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointments of Stephanos Ioannidis, PhD, as Executive Vice President, Drug Discovery and Catherine Scholz, PharmD, as Senior Vice President, Program Management.
“Drs. Ioannidis and Scholz are both dedicated leaders and excellent additions to our team as we mature our pipeline this year while continuing to leverage our ExoSight™ discovery platform,” said Michael Bruce, PhD, CEO of Exo Therapeutics. “Dr. Ioannidis has a strong record of delivering novel candidates into the clinic and experience that spans from early discovery to clinical development. Dr. Scholz has played a key role in the development and approval of multiple innovative medicines. Welcome to the team!”
“Exosites hold a tremendous amount of potential that may enable us to significantly expand the diversity of targets that we can pursue in drug discovery and in turn, the potential benefits we can deliver to patients,” said Dr. Ioannidis. “I look forward to leading the company’s discovery efforts and am excited to expand the horizons of this emerging approach.”
“I'm energized to join the committed and passionate team of scientists and drug developers at Exo and look forward to championing a culture of high-performance teaming to advance groundbreaking therapies,” said Dr. Scholz.
Dr. Ioannidis has over 20 years of experience in oncology, neuroscience, and inflammation drug development with a particular focus in early discovery to delivery of IND. Prior to joining Exo, Dr. Ioannidis was Executive Vice President, Head of Discovery at IFM Therapeutics where he led the company’s drug discovery group focused on innate immune system therapeutics. Dr. Ioannidis has also held roles of increasing responsibility at H3 Biomedicine, FORMA Therapeutics, and AstraZeneca R&D. Dr. Ioannidis earned his PhD in Synthetic Organic Chemistry from the Imperial College of Science, Technology and Medicine at University of London and completed his postdoctoral fellow at Harvard University.
Dr. Scholz brings over 20 years of experience in program management, portfolio strategy and clinical pharmacology. She was a key contributor to the development and approvals of vedolizumab, brentuximab vedotin and estradiol valerate/dienogest. Prior to joining Exo Therapeutics, Dr. Scholz was Vice President, Clinical Development at H3 Biomedicines, a subsidiary of Eisai Co., Ltd. Additionally, Dr. Scholz held leadership roles of increasing responsibility at Kura Oncology, EMD Serono, Millennium Pharmaceuticals and Bayer Schering Pharma. Dr. Scholz earned her Doctor of Pharmacy from Rutgers University and completed her fellowship training in clinical pharmacology at the University of Texas, MD Anderson Cancer Center.
About Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. For more information, visit www.exo-therapeutics.com.
